/Diazoxide Choline (Vykat XR) for Prader-Willi Syndrome-Associated Hyperphagia
Abstract

The FDA has approved diazoxide choline extended-release tablets (Vykat XR – Soleno Therapeutics) for treatment of hyperphagia in patients ≥4 years old with Prader-Willi syndrome. Diazoxide choline is the first drug to be approved in the US for this indication. Diazoxide oral suspension (Proglycem) has been available for years for management of symptomatic hypoglycemia.

RelatedView All
CitationsView All
Citing-
Cited By-